Herantis Pharma is a publicly listed (Finland, HRTIS and Sweden, HRNTS) drug development company aiming to revolutionize the treatment of diseases with unmet clinical needs. Based on leading academic research published in high-impact journals including Nature and Science, two ongoing clinical development programs explore the potential of its novel drug candidates in Parkinson’s disease and secondary lymphedema. Both Parkinson’s disease and lymphedema remain conditions in which current treatments only address symptoms and therefore do not enable long-term improvement for patients.
We believe that Herantis offers an attractive opportunity to address diseases with a large unmet medical need and to compete on the market for neurodegenerative diseases and secondary lymphedema. Additionally, the company’s technology could serve as a platform going into several diseases with similar pathologies. If strong clinical data is generated the company could find itself in an attractive position as an acquisition.
The key risks for Herantis are related to clinical and development risks of its candidates in terms of failed or delayed studies. Liquidity and financing risks are also important to consider, as Herantis is currently a development-stage company with negative cash flow. The competitive landscape could also be significantly different at the time when Herantis’ drug candidates could be approved.